Abstract
Breast cancer is the most common malignancy afflicting Western women today and is responsible for many deaths due to metastatic disease. Upregulation of the plasminogen-activation system (PAS) has been shown to correlate with poor prognosis in metastatic breast cancer and targeting this system represents an attractive strategy for the development of anti-metastasis prophylactic drugs. Two promising classes of PAS-targeting agents are inhibitors of the serine protease activity of urokinase plasminogen activator (uPA) and antagonists of the interaction of uPA with its cell surface receptor (uPAR). This review begins with a brief overview of the role of PAS in cancer metastasis before describing in detail a subset of the small molecules and peptides from the patent literature that target either uPA activity or uPA/uPAR interactions for use as anti-metastasis drugs.
Keywords: Breast cancer, metastasis, adjuvant chemotherapy, plasminogen activation system, uPA, protease, uPAR, inhibitor, antagonist, WX-UK1
Recent Patents on Anti-Cancer Drug Discovery
Title: Peptides and Small Molecules Targeting the Plasminogen Activation System: Towards Prophylactic Anti-Metastasis Drugs for Breast Cancer
Volume: 3 Issue: 1
Author(s): Joel D. A. Tyndall, Michael J. Kelso, Phillip Clingan and Marie Ranson
Affiliation:
Keywords: Breast cancer, metastasis, adjuvant chemotherapy, plasminogen activation system, uPA, protease, uPAR, inhibitor, antagonist, WX-UK1
Abstract: Breast cancer is the most common malignancy afflicting Western women today and is responsible for many deaths due to metastatic disease. Upregulation of the plasminogen-activation system (PAS) has been shown to correlate with poor prognosis in metastatic breast cancer and targeting this system represents an attractive strategy for the development of anti-metastasis prophylactic drugs. Two promising classes of PAS-targeting agents are inhibitors of the serine protease activity of urokinase plasminogen activator (uPA) and antagonists of the interaction of uPA with its cell surface receptor (uPAR). This review begins with a brief overview of the role of PAS in cancer metastasis before describing in detail a subset of the small molecules and peptides from the patent literature that target either uPA activity or uPA/uPAR interactions for use as anti-metastasis drugs.
Export Options
About this article
Cite this article as:
Tyndall D. A. Joel, Kelso J. Michael, Clingan Phillip and Ranson Marie, Peptides and Small Molecules Targeting the Plasminogen Activation System: Towards Prophylactic Anti-Metastasis Drugs for Breast Cancer, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (1) . https://dx.doi.org/10.2174/157489208783478711
DOI https://dx.doi.org/10.2174/157489208783478711 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem-Cell Transplantation for the Treatment of Solid Tumors in Adults: A Critical Review
Current Stem Cell Research & Therapy In Silico Design, Synthesis and Bioactivity of N-(2, 4-Dinitrophenyl)-3-oxo- 3-phenyl-N-(aryl) Phenyl Propanamide Derivatives as Breast Cancer Inhibitors
Current Computer-Aided Drug Design Absorption, Pharmacokinetics and Disposition of Biodegradable Nanoscale Preparations
Current Drug Metabolism A Comprehensive Review on Pharmacognostical Investigation and Pharmacology of Typhonium trilobatum
The Natural Products Journal Immunosuppressive Properties of Mesenchymal Stem Cells: Advances and Applications
Current Molecular Medicine Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma
Current Medicinal Chemistry Cellular Therapy for Ovarian Cancer: Experimental and Clinical Perspectives
Current Medicinal Chemistry The Complex Dynamics of Breast Cancer
Current Women`s Health Reviews The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy
Current Drug Targets Ontogeny of Human Conjugating Enzymes
Drug Metabolism Letters Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry An Introduction to the Nutrition and Metabolism of Choline
Central Nervous System Agents in Medicinal Chemistry The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Current Medicinal Chemistry Editorial (Thematic Issue: Revisiting the Revolution: Examining the Evolving Role of Antiangiogenic Therapy in Cancer)
Current Drug Targets Salient Structural Features of Human Lemur Tyrosine Kinase 3 (LMTK3) Domain from Molecular Dynamics Simulation Study
Current Biotechnology Triple-negative Breast Cancer and Poly(ADP-ribose) Polymerase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Delivery Systems for Applications in siRNA Technology
Drug Delivery Letters IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design The Interaction of Titanocene Y with Double-Stranded DNA: A Computational Study
Letters in Drug Design & Discovery Editorial [ Hot Topic: Novel Medicinal Chemistry Approaches to New Anti-cancer Agents (Guest Editor: Diane H. Boschelli) ]
Current Topics in Medicinal Chemistry